早期查孕期糖尿病和怀孕结果:一个系统性审查
1Obstetrics and Gynecology, Kanad Hospital, Abu Dhabi, ARE.
Cureus
|July 11, 2025
概括
在高风险怀孕中,在24周之前对妊娠糖尿病 (GDM) 的早期查不会改善母亲或新生儿的结果. 目前的证据表明,在24-28周的标准查中没有明显的临床优势.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 内分泌学 在内分泌学.
背景情况:
- 孕期糖尿病 (GDM) 通常是在怀孕24-28周之间被诊断出来的.
- 早期查 (≤20周) GDM正在获得高风险妇女的引力,但其临床实用性仍有争议.
- 现有的研究缺乏关于早期GDM查的好处的全面数据.
研究的目的:
- 系统地审查随机对照试验 (RCT),比较早期 (≤20周) 与标准 (24-28周) 预先存在糖尿病的孕妇GDM查.
- 评估早期GDM查对母亲和新生儿临床结果的影响.
- 评估关于将GDM查转移到怀孕早期的好处和潜在缺点的证据.
主要方法:
- 2000年1月至2025年3月期间发表的RCT的系统审查.
- 搜索了多个数据库,包括MEDLINE,Embase,Cochrane控制试验中央注册表,科学网络,Scopus,CINAHL和临床试验.gov.gov.
- 包括3项涉及2540名女性的RCT,其中2项专注于肥胖女性,1项针对更广泛的高风险队列.
主要成果:
- 早期查发现了更多的GDM病例 (15.0% vs 12.0%),但没有提供任何临床优势.
- 在早期和标准查组之间,新生儿组合不良事件是可比的 (53.7%与48.6%对比).
- 对于宏观 (>4,000 g),与怀孕相关的高血压或剖腹产的发病率没有观察到显著的益处.
结论:
- 目前的证据表明,在24周之前启动GDM查不会改善母亲或新生儿的结果.
- 早期查可能会导致干预增加,但没有明显的临床益处.
- 需要进一步进行大规模实用性研究,以评估成本效益,并证明在特定高风险人群中进行有针对性的早期查是合理的.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes: Symptoms, Diagnosis, and Complications
702
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
702
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Diabetes: Management and Pharmacotherapy
408
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
408


